Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$85.95 USD
+1.56 (1.85%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $85.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Merit Medical (MMSI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$94.10 | $125.00 | $81.00 | 11.51% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Merit Medical comes to $94.10. The forecasts range from a low of $81.00 to a high of $125.00. The average price target represents an increase of 11.51% from the last closing price of $84.39.
Analyst Price Targets (10)
Broker Rating
Merit Medical currently has an average brokerage recommendation (ABR) of 1.70 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.78 a month ago based on nine recommendations.
Of the 10 recommendations deriving the current ABR, five are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 50% and 30% of all recommendations. A month ago, Strong Buy made up 44.44%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MMSI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.70 | 1.70 | 1.78 | 1.78 | 1.78 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
7/2/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
7/1/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
6/28/2024 | Robert W. Baird & Co. | David Rescott | Not Available | Strong Buy |
4/30/2024 | Piper Sandler | Jason Bednar | Strong Buy | Strong Buy |
4/30/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
4/11/2024 | C.L. King & Associates | Kristen M Stewart | Not Available | Moderate Buy |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/11/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.70 |
ABR (Last week) | 1.70 |
# of Recs in ABR | 10 |
Average Target Price | $94.10 |
LT Growth Rate | 10.80% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | 0.88 |